icon-    folder.gif   Conference Reports for NATAP  
  20th International AIDS Conference
July 20-25, 2014
Melbourne, Australia
Back grey_arrow_rt.gif
Aging, Comorbidities - Inflammation/Activation-Gut, Complications - Bone, Neuro/Brain, Kidney, Heart Disease, HPV, Pnuemococcal disease - Adherence, Tolerability/Adverse Events (50 reports)
  from Jules: a lot of attention to aging science. But with 50% and greater of HIV-infected individuals aging past 50 years old & a significant percent over 60 years old these individuals are and will increasingly as they get older have to deal with a number or personal health issues not being addressed including depression and isolation at higher rates than HIV-unifected, housing & income concerns, worsening mobility, increased need for geriatric specialty care, potentially increasing cognitive concerns & falls which often result in fractures, and increasing rates of other comorbidities like kidney disease and heart disease. Although the Office of AIDS Research (OAR) and many researchers including the ACTG are addressing scientific issues as 10s of millions of dollars in grant support has newly become available to researchers, what is not receiving any attention are these personal & sociological concerns listed above. Small support groups for aging HIV+ individuals are recently cropping up in NYC but the issue regarding the needs for beefed up services gets no attention. The City of NY and other cities to begin with need an HIV/Aging Ombudsman to be a liaison between aging patients and their increasing needs. We need an infrastructure in HIV/AIDS that addresses these concerns but unfortunately there is no discussion about this at the Federal or local levels of govt including in Congress, Washington DC, at the NIH or the CDC or at the White House. Its great that we are deviating so much effort and finances to try to find a cure for HIV but these real-world aging concerns are getting no attention.
Gait Speed in Older HIV Group Not Fast Enough to Cross Street Safely - written by Mark Mascolini - (07/28/14)
Diminished Physical Function in Older HIV+ Adults Despite Successful Antiretroviral Therapy - (07/28/14)
The burden of subclinical heart and lung disease detected on thoracic CT scans of HIV-infected individuals on antiretroviral therapy - (08/04/14)
Inflammation/Activation Markers Drop With ATV, DRV, RAL, But Not Completely - ACTG Study - written by Mark Mascolini - (07/23/14)
Neurocognitive Disorder Rates Differ by US vs Local Standards in Australian MSM - Mark Mascolini - (07/25/14)
Predictors of Neurocognitive Decline and Rebound in US CHARTER Group - Mark Mascolini - (07/25/14)
Longer ART, Better CD4 Gain Protect From Neurocognitive Decline in ACTG Analysis - written by Mark Mascolini - (07/25/14)
Higher One-Year Risk of CVD or Diabetes Per BMI Unit Gained on ART - written by Mark Mascolini - (07/23/14)
Inflammatory Cytokine/IL-10 Ratios Tied to Regional Brain Atrophy With HIV - written by Mark Mascolini - (07/24/14)
Efavirenz Not Tied to Neurocognitive Impairment in Large Single-Center Study - written by Mark Mascolini - (07/24/14)
Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens - (07/25/14)
COPD Rate 7% in Global HIV Cohort--Half With COPD Never Smoked - written by Mark Mascolini - (07/23/14)
Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men (07/25/14)
Anal Cancer Precursor More Common in HIV+ Than HIV- MSM; Clearance Rate High - written by Mark Mascolini - (07/24/14)
Quadrivalent HPV Vaccine Elicits Antibody and Cell Responses in HIV+ Teens, Young Adults - written by Mark Mascolini - (07/23/14)
ART in Acute Infection Quells Inflammation But Does Not Restore Gut CD4s - (08/11/14)
Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis - (08/08/14)
Probiotic and IL-21 Treatment Promotes Th17 Cell Recovery in ARV-Treatment of Pigtail Macaques - (08/06/14)
Body mass index (BMI) and change in levels of immune activation post- ART initiation in diverse low- and middle-income settings - (08/05/14)
Improvement of kidney function after anti HCV therapy in hepatitis C/HIV coinfection - (07/28/14)
IAC Plenary on HIV/Aging & NATAP Reports on HIV/Aging-Complications / HCV /Activation / Inflammation/Kidney/Anal Cancer-HSIL clearance/COPD/Neuro-Cognitive Disorders - (08/04/14)
High Inflammation/Activation Markers Before and During ART Predict Death in MACS - Mark Mascolini - (08/04/14)
Raltegravir May Offer Gut Microbe Advantages Compared With Nonnucleosides - Mark Mascolini - (08/04/14)
SIV-infected rhesus macaques receiving suppressive cART have continued GI damage, inflammation, immune activation and persistent low-level viral replication within lymphoid tissues"Suggesting that HIV Cure strategies will need to address sources of residual inflammation/immune activation to be successful" - (07/28/14)
Effect of monthly calcidiol supplementation on secondary hyperparathyroidism and bone mineral density in HIV-infected patients with vitamin D deficiency (07/31/14)
Monthly Vitamin D May Improve Bone Density in People With HIV - Mark Mascolini (07/28/14)
Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14)
Monocyte activation markers remain significantly elevated in virologically suppressed HIV+ individuals to a level equivalent to an additional 4 years of normal ageing (07/30/14)
Treatment with the histone deacetylase inhibitor Panobinostat markedly reduces chronic inflammation in HIV-infected patients (07/29/14)
Real-World Adherence among Patients Receiving Single versus Multiple Tablet Regimens for HIV-1 Infection, and Associations between Adherence and Viral Suppression: A Systematic Literature Review and Meta- Analysis (07/29/14)
Cost-Effectiveness of Single versus Multiple Tablet Regimens for Treatment of HIV-1 Infection in the US (07/29/14)
Do Single Tablet Regimens Translate into More Durable HIV Treatments? Evidence from the Canadian Observational Cohort (CANOC) (07/29/14)
Measuring Patient Views of HIV Treatments: Comparing Dolutegravir With Darunavir/r in the FLAMINGO Study - (07/28/14)
Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir - written by Mark Mascolini - (07/23/14)
Tenofovir(TFV), Emtricitabine(FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Subjects - (07/28/14)
Week 144 Renal Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) from Two Phase 3 Randomized Controlled Trials - (07/28/14)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (07/28/14)
STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults through Week 96 with a Favorable Safety Profile for Abnormal Dreams and Dizziness - (07/28/14)
STRATEGY Studies (GS-115 and GS-121): Safety Analysis of Switching to STB from a RTV-Boosted PI or NNRTI Plus TVD Regimen - (07/28/14)
Obesity Doubles Chances of More Inflammation and Monocyte Activation With HIV - written by Mark Mascolini - (07/28/14)
Activation Marker Levels With Undetectable Viral Load Match Those of Uninfected People 4 Years Older - written by Mark Mascolini - (07/28/14)
Pneumococcal Disease Rate Drops in HIV Group But Still Far Exceeds HIV-Negative Rate - written by Mark Mascolini - (07/28/14)
Prenatal Exposure to Zidovudine and Risk for Ventricular Septal Defects and Congenital Heart Defects: Data From the Antiretroviral Pregnancy Registry (APR) (07/21/14)
Liver Markers Worse in Youth With Than Without HIV and Climb Over Time - Written by Mark Mascolini (07/21/14)
FIB-4 Predicts Major Liver Complications and Death in HCV+ People Starting ART - (07/21/14)